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Gilbert Syndrome (GS) is an inherited form of mild 
unconjugated hyperbilirubinemia characterized by 
decreased bilirubin UDP-glucuronosyl transferase 
(UGT1A1) activity. GS is the most common alteration of 
the hepatic bilirubin metabolism, occurring in 2-12% of 
the population .1-5 A nonsense mutation of the UGT1A1 
gene was identified in a patient with Crigler-Najjar 
Syndrome in 1992, but it was only in 1995 that 
mutations in UGT1A1 that caused GS were discovered. 
The most common genetic variant of the UGT1A1 gene 
is a TA insertion in the repetitive TATA-Box of the gene 
promoter, which normally consists of six repeats. 2 The 
TA(?) allele causes reduced expression of the gene, and 
homozygosity of this allele is typically associated with a 
mild form of GS1. The aim of our study was to 
determine the frequency of UGT1A1 gene variants in 
Portuguese patients with clinical diagnosis of GS. We 
screened 25 Portuguese patients with clinical diagnosis 
of GS: 6 females, ages 4-30 years, and 19 males, ages 
1-35 years. The diagnosis of GS was based on the 
standard criteria6. The mean ( +/- SD) total bilirubin 
concentration was 45,15 +/- 25,18 mmoi/L. Genomic 
DNA was extracted from peripheral blood leukocytes 
using standard methods. Screening of the variants in 
the promoter of the UGT1Al gene was performed by 
polymerase chain reaction with primers described by 
Bancroft et al.? Analysis of the amplified DNA fragments 
was performed by automated capillary electrophoresis. 
Analysis of UGT1A1 promoter variants (Figure 1) 
revealed that 22 (88%) of the GS patients were 
homozygous for the mutant allele (TA(7)/TA(7)), and 3 
(12%) were heterozygotes (TA(6)/ TA(?)). The high 
frequency of SG patients presenting this mutation is 
similar to that found in other popu!ations, namely in the 
Italian population where the homozygote frequency was 
seen to be 80%. 3 Based on the frequency observed in 
Caucasians, in several studies of small series, Beutler et 
al. 5 calculated a homozygote frequency of 15%. This 
predicted value is higher than that of patients with a 
clinical diagnosis of GS, which probably reflects the 
existence of other inherited or acquired factors affecting 
bilirubin metabolism, in addition to reduced 
alucuronidation caused bv the TA insertion. 2 Male 
element had a more significant elevation in serum 
bilirubin than the females. This is possibly due to the 
greater bilirubin load per kilogram of body weight in 
males or the inhibition of enzymatic glucuronidation by 
androgenic steroids, or both. 2 The higher levels may 
explain the sample bias of 19:6 (men/women) in our 
group of GS patients. In conclusion, our results suggest 
that the insertion of the TA dinuclotide in the promoter 
region of the gene of the UGT1A1 is the main cause of 
GS in the Portuguese population. 
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